Diabetes und Niere – Diabetische Nephropathie auf dem Vormarsch

Die diabetische Nephropathie ist neben der vaskulären Nephropathie die häufigste Nierenerkrankung in den entwickelten Industriestaaten. Die wichtigsten Faktoren für ihre Entstehung sind genetische Prädisposition, arterielle Hypertonie und Hyperglykämie. Eine Prävention ist nur durch eine frühzeitige Optimierung von Blutdruck und Blutzucker – praktisch unmittelbar nach Stellung der Diabetesdiagnose möglich. Für die Progressionshemmung hat sich die Blutdruckoptimierung als entscheidend erwiesen, eine normnahe Blutzuckereinstellung ist dabei eher von nachgeordneter Bedeutung.

Diabetic nephropathy has become the most common cause of end stage renal disease in the industrialized countries. Genetic background, hyperglycemia and hypertension are important causative factors, whereas the latter one is also responsible for disease progression. An early optimal treatment of hypertension and hyperglycemia accompanied by life style modification are the best therapeutic strategies to prevent diabetic kidney damage. Once diabetic nephropathy has been occurred, an optimal blood pressure control is mandatory and its effect is superior over blood glucose control.

diabetic nephropathy - microalbuminuria - oxidative stress - diabetes mellitus

Literatur

• 1 Adler AI, Stevens RJ, Manley SE et al.. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).  Kidney Int. 2003;  63 225-232
• 2 Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus.  N Engl J Med. 1999;  341 1127-1133
• 3 Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics.  Kidney Int. 2004;  66 2095-2106
• 4 Pezzolesi MG, Poznik GD, Mychaleckyj JC et al.. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes.  Diabetes. 2009;  58 1403-1410
• 5 Hotamisligil GS. Inflammation and metabolic disorders.  Nature. 2006;  444 860-867
• 6 Rossing K, Mischak H, Dakna M et al.. Urinary proteomics in diabetes and CKD.  J Am Soc Nephrol. 2008;  19 1283-1290
• 7 Adler AI, Stratton IM, Neil HA et al.. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.  BMJ. 2000;  321 412-419
• 8 Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.  Lancet. 1993;  1 1175-1179
• 9 Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes.  N Engl J Med. 2008;  359 1565-1576
• 10 Pohl MA, Blumenthal S, Cordonnier DJ et al.. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.  J Am Soc Nephrol. 2005;  16 3027-3037
• 11 Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy.  N Engl J Med. 2008;  358 2433-2446
• 12 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 13 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 14 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
• 15 Nathan DM, Cleary PA, Backlund JY et al.. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.  N Engl J Med. 2005;  353 2643-2653
• 16 Ismail-Beigi F, Craven T, Banerji MA et al.. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.  Lancet. 2010;  376 419-430
• 17 Patel A, MacMahon S, Chalmers J et al.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
• 18 Duckworth W, Abraira C, Moritz T et al.. Glucose control and vascular complications in veterans with type 2 diabetes.  N Engl J Med. 2009;  360 129-139
• 19 Pistrosch F, Herbrig K, Kindel B et al.. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.  Diabetes. 2005;  54 2206-2211
• 20 Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.  Clin J Am Soc Nephrol. 2009;  4 1523-1528

1 Diabetes Control and Complications Trial

2 United Kingdom Prospective Diabetes Study

3 Action to Control Cardiovascular Risk in Diabetes

4 Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation

5 Veterans Affairs Diabetes Trial

Korrespondenz